NAS10027,087+1.72%S&P7,401+0.65%GOLD$4,073−1.00%BTC$75,828−0.15%VIX24.55−12.88%latest tape · as of 20:03 UTC
The Screen · Real Estate · REIT - Healthcare Facilities
Healthcare Realty Trust Incorporated
HR · the NYSE · USD · Market cap $6.8B · 539 employees
Healthcare Realty Trust Incorporated is a real estate investment trust (REIT) that owns and operates medical outpatient buildings primarily located around market-leading hospital campuses.
FAIL · Does not pass the screen
19.07 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price19.07 USD at the 5 Nov 2026 close
Our value readOvervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.23, read 2026-11-02
Ethical does not pass the values gate
Price19.07 USD
Fair value10.93
Ethical score70.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-26Read Markup17.76+7.4% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-22Read Distribution17.76+7.4% to today Markdown gives way to Distribution after an 8% slide in 7 weeks
2026-09-01Read Markdown19.39-1.7% to today ✓Markup gives way to Markdown after a 10% slide in 4 weeks
2026-08-01Read Markup21.53-11.4% to today Accumulation gives way to Markup with results news in the headlines
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Healthcare Realty Trust Incorporated holds its Markup at $19.07. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$19.07
Valuation
N/A trailing · 486.00 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.79
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
45.03%
Below 33%
Interest-bearing debt is 45.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
2.13%
Below 49%
Money owed to the company is 2.1% of assets, under the 49% limit.
Pass
Revenue purity
0.10%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Healthcare Realty Trust's business is in a permissible area, but its interest-bearing debt is about 45% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HR's ethical verdict changes
Today HR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $10.93 fair value estimate.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 74.5% above the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +13% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $10.93, with a range of $10.93 to $12.57, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medical Buildings Look Safe But Numbers Say Otherwise
Picture a landlord whose tenants are hospitals yet half the lights are off and revenue is sliding. Healthcare Realty owns outpatient clinics clustered around big campuses, a steady sounding niche on paper. The business still posts revenue down 6 percent, a 17 percent loss margin and negative return on equity, which leaves little room for the acquisitions it claims will drive growth.
We pass because the shares trade at more than double our assessed fair value with a forward multiple above 1,000 times earnings. Analyst consensus sits at a neutral hold and a price target matching the current quote, offering no margin of safety. An ethical screen clears the name, yet the valuation and operating trends leave nothing attractive to pursue.
Further downside sits in execution risk around property deals funded by a stretched balance sheet, plus any slowdown in hospital leasing demand. The gap between price and fundamentals is wide enough that even modest misses could widen it further. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$19.44+8.3%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20.
2026-10-29Markup$17.95+1.1%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$17.76+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$17.76+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup · changed$17.76+0.0%Entry 12
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$17.76+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$17.76+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$17.76+0.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$17.22-1.2%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (11 analysts) rates it hold, with a mean price target of $20.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
